. home.aspx

NEWS

home.aspx
   


Tiaki hires Bruhn as CEO for Alzheimers drug discovery push

July 11, 2019 / Nick Paul Taylor

Tiaki Therapeutics has appointed Suzanne Bruhn as CEO. Bruhn, a serial biotech CEO, arrives at Tiaki shortly after the Alzheimer’s disease startup entered into a collaboration with Eisai. The Dementia Discovery Fund (DDF), an investment vehicle backed by seven big biopharma companies, formed and seeded Tiaki to support efforts to identify modulators of microglial function. Tiaki thinks targeting microglia, immune cells found in the brain, could lead to disease-modifying treatments for a range of neuroinflammatory conditions, starting with Alzheimer’s. Barbara Tate, chief strategy officer at DDF, guided Tiaki through its early years as interim CEO but has now stepped aside to let Bruhn take over as the permanent leader of the neuroinflammation startup. The leadership change comes as Tiaki looks to build on its early research activities. “Sue’s appointment comes at an exciting time for Tiaki, as we launch the company into drug discovery based on targets emerging f...